DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer
Authors' conclusion
These results show a progressive increase in DNA methylation alterations, mainly hypomethylation, during PTC and FTC metastatic progression, suggesting a linear model, though the DNA methylation dynamics differs between the two histological types.
Study context
- Population
- Patients with differentiated thyroid cancer (DTC) who underwent surgery at five university hospitalssamples, discovery series
- Participants
- 97 samples
- Exposure
- Methylation in normal tissue, non-metastatic and metastatic primary DTC and paired metastases
- Normal tissuen = 15reference
- non-mDTCn = 30
- mDTCn = 35
- Paired metastasesn = 17
- Outcome
- DNA methylation dynamics during DTC progression
Methodological detailsmulticenter, discovery and independent validation series
- Multicenter
- Discovery and independent validation series
Main finding
As reported in the abstract
Overlap of differentially methylated CpGs (DMe-CpGs) between non-mPTC and non-mFTC (non-mPTC DMe-CpGs present in non-mFTC)
14%
Overlap of DMe-CpGs between mPTC and mFTC (mPTC DMe-CpGs present in mFTC)
60%
De novo DMe-CpGs from mPTC present in distant metastases (DM)
83%
De novo DMe-CpGs from mFTC present in DM
40%
Observational data: associations, not effects.
Further findings
Prognostic CpG signature for DM
- Validated CpG signature in primary tumors distinguishing non-mDTC from mDTC, regardless of histology (number of CpGs)
- 156
- Validated in independent series of 17 non-mDTC and 13 mDTC
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →